“She’s an example of this emerging face of cancer that's really quite challenging and quite alarming,” Deignan said.

For many cancer patients, side effects from radiation can be debilitating. But a new way of delivering radiation treatment ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

ImmunityBio, Inc. , a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC ...

First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the American Urological Association 2025 Annual ...

First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological Association ...